Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):976–978. doi: 10.1128/aac.39.4.976

Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.

N Rastogi 1, V Labrousse 1, A Bryskier 1
PMCID: PMC162664  PMID: 7786006

Abstract

Recent reports have shown that roxithromycin possesses significant activity against atypical mycobacteria, including the Mycobacterium avium complex (MAC), and that its extracellular anti-MAC activity is further enhanced in two- or three-drug combinations with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine. In accordance with the above data, the anti-MAC potential of roxithromycin used alone and in combination with the above-mentioned antituberculous drugs was screened intracellularly against five clinical MAC isolates (from both human immunodeficiency virus-positive and human immunodeficiency virus-negative patients), phagocytized by human monocyte-derived macrophages. The results showed that roxithromycin used alone and within clinically achievable levels was active against all of the MAC isolates tested. Screening of two-drug combinations showed that both rifampin and clofazimine further increased the intracellular activity of roxithromycin against all five isolates by 35 to 80% (ethambutol, ofloxacin, and amikacin resulted in increased intracellular activity against one, two, and four isolates, respectively). For the three-drug combinations, the combination of roxithromycin plus ethambutol used with rifampin or clofazimine was the most uniformly active against all five MAC isolates, with activity increases of 42 to 90%, followed by roxithromycin plus ethambutol used with amikacin, which resulted in activity increases of 15 to 90%. The overall level of intracellular killing after 5 days of drug addition, in comparison with growth in untreated controls, varied from 1 to 3 log units depending on the individual MAC isolate and/or drug combination used.

Full Text

The Full Text of this article is available as a PDF (192.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agins B. D., Berman D. S., Spicehandler D., el-Sadr W., Simberkoff M. S., Rahal J. J. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis. 1989 Apr;159(4):784–787. doi: 10.1093/infdis/159.4.784. [DOI] [PubMed] [Google Scholar]
  2. Baron E. J., Young L. S. Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome. Diagn Microbiol Infect Dis. 1986 Sep;5(3):215–220. doi: 10.1016/0732-8893(86)90004-0. [DOI] [PubMed] [Google Scholar]
  3. Benson C. A., Ellner J. J. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis. 1993 Jul;17(1):7–20. doi: 10.1093/clinids/17.1.7. [DOI] [PubMed] [Google Scholar]
  4. Gemmell C. G. Macrolides and host defences to respiratory tract pathogens. J Hosp Infect. 1991 Sep;19 (Suppl A):11–19. doi: 10.1016/0195-6701(91)90213-r. [DOI] [PubMed] [Google Scholar]
  5. Gordon S. M., Horsburgh C. R., Jr, Peloquin C. A., Havlik J. A., Jr, Metchock B., Heifets L., McGowan J. E., Jr, Thompson S. E., 3rd Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis. 1993 Dec;168(6):1559–1562. doi: 10.1093/infdis/168.6.1559. [DOI] [PubMed] [Google Scholar]
  6. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mansfield R. E. Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg. 1974 Nov;23(6):1116–1119. doi: 10.4269/ajtmh.1974.23.1116. [DOI] [PubMed] [Google Scholar]
  8. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med. 1993 Sep 16;329(12):898–904. doi: 10.1056/NEJM199309163291228. [DOI] [PubMed] [Google Scholar]
  9. Rastogi N., Barrow W. W. Laboratory and clinical aspects of the Mycobacterium avium epidemic: contributing factors associated with variability of drug susceptibility and immune responsiveness, and the multifaceted nature of pathogenicity. Res Microbiol. 1994 Mar-Apr;145(3):167–168. doi: 10.1016/0923-2508(94)90012-4. [DOI] [PubMed] [Google Scholar]
  10. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., David H. L. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? Antimicrob Agents Chemother. 1981 Nov;20(5):666–677. doi: 10.1128/aac.20.5.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rastogi N., Goh K. S., Bryskier A. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother. 1994 Jun;38(6):1433–1438. doi: 10.1128/aac.38.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rastogi N., Goh K. S., Bryskier A. In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrob Agents Chemother. 1993 Jul;37(7):1560–1562. doi: 10.1128/aac.37.7.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rastogi N., Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Mar;35(3):462–470. doi: 10.1128/aac.35.3.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rastogi N., Labrousse V., Goh K. S., De Sousa J. P. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother. 1991 Dec;35(12):2473–2480. doi: 10.1128/aac.35.12.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Saint-Marc T., Marneff E., Touraine J. L. Infections à Mycobacterium avium intracellulare. Traitement par la double association clarithromycine-clofazimine. 18 observations. Presse Med. 1993 Dec 4;22(38):1903–1907. [PubMed] [Google Scholar]
  16. Wise R., Griggs D., Andrews J. M. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S83–S89. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES